Analyzing Fresh Tracks Therapeutics (NASDAQ:FRTX) and X4 Pharmaceuticals (NASDAQ:XFOR)
Analyzing Fresh Tracks Therapeutics (NASDAQ:FRTX) and X4 Pharmaceuticals (NASDAQ:XFOR)
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) and X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Fresh Track Treeutics(纳斯达克：FRTX-GET评级)和X4制药(纳斯达克：XFOR-GET评级)都是小盘医疗公司，但哪一家是优势投资？我们将根据这两家公司的股息实力、分析师建议、收益、机构所有权、估值、盈利能力和风险对它们进行比较。
Valuation & Earnings
估值与收益
This table compares Fresh Tracks Therapeutics and X4 Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
此表比较了Fresh Track Treeutics和X4 PharmPharmticals的营收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | 16.24 | -$39.47 million | ($8.39) | -0.27 |
| X4 Pharmaceuticals | $3.00 million | 25.16 | -$88.70 million | ($2.82) | -0.39 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 新奇轨道治疗公司 | $400,000.00 | 16.24 | -3,947万元 | ($8.39) | -0.27 |
| X4制药公司 | 300万美元 | 25.16 | -8870万美元 | ($2.82) | -0.39 |
Fresh Tracks Therapeutics has higher earnings, but lower revenue than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fresh Track治疗公司比X4制药公司有更高的收益，但收入更低。X4制药的市盈率低于Fresh Track Treeutics，这表明它目前是两只股票中更负担得起的一只。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| X4 Pharmaceuticals | N/A | -184.37% | -92.38% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 新奇轨道治疗公司 | -453.11% | -133.55% | -108.52% |
| X4制药公司 | 不适用 | -184.37% | -92.38% |
Analyst Recommendations
分析师建议
This is a breakdown of current recommendations and price targets for Fresh Tracks Therapeutics and X4 Pharmaceuticals, as reported by MarketBeat.
这是MarketBeat报道的Fresh Track治疗公司和X4制药公司目前的建议和价格目标的细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| X4 Pharmaceuticals | 0 | 0 | 5 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 新奇轨道治疗公司 | 0 | 0 | 0 | 0 | 不适用 |
| X4制药公司 | 0 | 0 | 5 | 0 | 3.00 |
Fresh Tracks Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 76.99%. X4 Pharmaceuticals has a consensus target price of $6.86, indicating a potential upside of 529.10%. Given X4 Pharmaceuticals' higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Fresh Tracks Therapeutics.
Fresh Track治疗公司目前的共识目标价为4.00美元，表明潜在上行空间为76.99%。X4 PharmPharmticals的共识目标价为6.86美元，表明潜在上行529.10%。鉴于X4制药公司更有可能上行，分析师显然认为X4制药公司比Fresh Track治疗公司更有利。
Institutional and Insider Ownership
机构和内部人持股
7.7% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 56.5% of X4 Pharmaceuticals shares are held by institutional investors. 4.5% of Fresh Tracks Therapeutics shares are held by company insiders. Comparatively, 95.9% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Fresh Track治疗公司7.7%的股份由机构投资者持有。相比之下，X4制药56.5%的股份由机构投资者持有。Fresh Track治疗公司4.5%的股份由公司内部人士持有。相比之下，X4制药95.9%的股份由公司内部人士持有。强大的机构持股表明，对冲基金、捐赠基金和大型基金经理相信，从长期来看，一只股票的表现将好于大盘。
Volatility and Risk
波动性和风险
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.
Fresh Track治疗公司的贝塔系数为0.29，这表明其股价的波动性比标准普尔500指数低71%。相比之下，X4制药的贝塔系数为0.48，这表明其股价的波动性比标准普尔500指数低52%。
Summary
摘要
X4 Pharmaceuticals beats Fresh Tracks Therapeutics on 10 of the 13 factors compared between the two stocks.
在两只股票之间的13个因素中，X4制药公司在10个因素上击败了Fresh Track治疗公司。
About Fresh Tracks Therapeutics
关于Fresh Track治疗公司
(Get Rating)
(获取评级)
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Fresh Track治疗公司是一家临床阶段的制药公司，致力于开发各种处方疗法，用于治疗美国的自身免疫、炎症和其他令人衰弱的疾病。该公司开发的产品包括：已完成治疗原发性腋窝多汗症的第三阶段临床试验的索吡溴铵；用于治疗自身免疫和炎症性疾病的口服DYRK1A抑制剂BBI-02；以及用于潜在治疗自体炎症和罕见遗传性疾病的干扰素基因共价刺激物BBI-10，以及下一代激酶抑制剂。它与Carna Biosciences，Inc.，Voronoi Inc.，Bodor实验室，Inc.和Nicholas S.Bodor博士以及Anges，Inc.签订了许可和合作协议。该公司前身为Brickell Biotech，Inc.，并于2022年9月更名为Fresh Track治疗公司。Fresh Track治疗公司成立于2009年，总部设在科罗拉多州博尔德市。
About X4 Pharmaceuticals
关于X4制药公司
(Get Rating)
(获取评级)
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
X4制药公司是一家生物技术公司，致力于开发治疗传染病的人类抗体。该公司专注于通过开发治疗罕见疾病的新疗法来恢复健康的免疫系统功能。其正在筹备的产品包括X4P-001、X4P-002和X4P-003。该公司由Henri A.Termeer、Keith T.Flaherty、Renato T.Skerlj、Richard Peters和Paula Ragan于2010年创立，总部位于马萨诸塞州波士顿。
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受新闻和评级的新轨道治疗每日-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对Fresh Track Treeutics和相关公司的评级的每日摘要。